Cyclacel Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1996-01-01

Employees: 12

Market Cap: -

Website: http://www.cyclacel.com

Introduction: Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Clinical Trials

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched

Cyclacel Pharmaceuticals completed enrollment of 12 patients in Cohort 8 of its Phase 2 study of fadraciclib, a CDK2/9 inhibitor, targeting advanced solid tumors and lymphoma with CDKN2A/B abnormalities. Safety and efficacy data will be presented at the ENA 2024 conference.

investing.com

4 months ago

Cyclacel halts dividend on preferred stock

Cyclacel Pharmaceuticals suspends its 6% Convertible Exchangeable Preferred Stock dividend, reassessing payments quarterly. The company faces potential delisting from Nasdaq due to non-compliance with minimum stockholders' equity, and has changed its certifying accountant to Crowe LLP. Cyclacel reported a net loss of $3.3 million and expects to fund programs until year-end, with progress in its fadraciclib study. InvestingPro data shows Cyclacel's revenue decline and operational challenges, with the stock in oversold territory.